Welcome to our dedicated page for Oric Pharmaceuticals SEC filings (Ticker: ORIC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ORIC is a clinical stage oncology company with common stock registered under Section 12(b) of the Exchange Act and listed on The Nasdaq Global Select Market under the symbol ORIC, as reflected in its Form 8-K filings.
Investors can review current reports on Form 8-K in which ORIC discloses material events such as quarterly financial results, clinical program updates, and corporate presentations. For example, the company has filed 8-Ks to announce financial results for quarters ended June 30 and September 30, 2025, to furnish updated ORIC-944 corporate presentation slides, and to provide an enozertinib (ORIC-114) program update summarizing Phase 1b trial data. Certain 8-Ks also describe strategic pipeline prioritization measures, including workforce reductions and a focus on lead programs ORIC-944 and enozertinib.
ORIC’s filings include details on its status as an emerging growth company, the registration of its common stock on The Nasdaq Global Select Market, and exhibits such as press releases and investor presentations. These documents also contain cautionary notes regarding forward-looking statements and refer readers to risk factor discussions in periodic reports like Form 10-Q.
On Stock Titan, ORIC’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points of lengthy filings by highlighting items such as reported financial results, clinical milestones, strategic changes, and capital raising activities. Users can quickly see what each 8-K covers, identify attached exhibits such as presentations, and understand how new disclosures may relate to ORIC’s oncology pipeline and Nasdaq-listed equity.
In addition to 8-Ks, this page links to ORIC’s other SEC documents available on EDGAR, allowing investors to follow the company’s regulatory history, governance disclosures, and risk factor updates as its clinical programs advance.
Oric Pharmaceuticals Chief Financial Officer Dominic Piscitelli reported option exercises and share sales in Oric Pharmaceuticals, Inc. common stock. On
On the same date, he then sold 52,000 shares of common stock in open-market transactions at a weighted average price of
ORIC Pharmaceuticals, Inc. is offering up to $200.0 million of common shares through a renewed at-the-market program under its existing Sales Agreement with Jefferies LLC, supported by a new 2026 prospectus supplement under its automatic shelf registration.
The company previously sold 13,478,432 shares for approximately $139.7 million in gross proceeds under a 2024 prospectus supplement, and no further sales will occur under that earlier supplement. A legal opinion from Wilson Sonsini Goodrich & Rosati related to the new offering is filed as an exhibit.
ORIC Pharmaceuticals filed a prospectus supplement to increase its at-the-market sales program with Jefferies to permit up to
The supplement states
ORIC Pharmaceuticals, a clinical-stage oncology company, filed its annual report outlining progress on two lead drug candidates and its 2025 financials. The company is advancing rinzimetostat for metastatic castration-resistant prostate cancer toward a first global Phase 3 trial planned for the first half of 2026, and enozertinib for EGFR-mutated lung cancer toward potential Phase 3 monotherapy development.
In 2025, ORIC recorded research and development expenses of $109.8 million and general and administrative expenses of $33.2 million, leading to a net loss of $129.5 million. Cash, cash equivalents and investments totaled $392.3 million as of December 31, 2025, after raising substantial capital through a $125 million May 2025 private placement and approximately $117.6 million of at-the-market share sales.
The company expects its current cash resources to fund its operating plan into the second half of 2028, even after a strategic pipeline refocus and roughly 20% workforce reduction to concentrate on its two lead clinical programs.
ORIC Pharmaceuticals reported fourth quarter and full-year 2025 results alongside major clinical progress in prostate and lung cancer. The company ended December 31, 2025 with $392.3 million in cash, cash equivalents and investments and expects this to fund its operating plan into the second half of 2028.
ORIC raised a total of $264 million in 2025 from a private placement and its ATM program, plus an additional $20.0 million afterward. Full-year R&D expenses were $109.8 million and G&A expenses were $33.2 million, leading to a net loss of $129.5 million, or $1.47 per share.
Clinically, rinzimetostat showed promising Phase 1b data in metastatic castration-resistant prostate cancer, with 55% of patients achieving PSA50 responses and 59% achieving ctDNA clearance, supporting plans for a Phase 3 trial in 1H 2026. Enozertinib generated strong systemic and intracranial responses in EGFR exon 20 and EGFR PACC-mutated NSCLC, with first-line data updates expected in the second half of 2026.
ORIC Pharmaceuticals’ institutional holders led by Venrock Healthcare Capital Partners report a 5.8% beneficial stake in the company’s common stock. The group, including several Venrock funds and individuals Nimish Shah and Bong Koh, collectively owns 5,676,230 ORIC common shares as of December 31, 2025.
The ownership is spread across VHCP III, VHCP Co-Investment III, and VHCP EG funds, with control entities VHCP Management III and VHCP Management EG. The percentage is calculated using 97,389,279 shares outstanding as of November 5, 2025, from ORIC’s Form 10-Q, and the group certifies the holdings are not for changing or influencing control.
BlackRock, Inc. has disclosed a significant passive ownership position in ORIC PHARMACEUTICALS INC common stock. BlackRock reports beneficial ownership of 5,473,145 shares, representing 5.6% of the outstanding common stock as of the reporting date of 12/31/2025.
BlackRock has sole power to vote 5,388,358 shares and sole power to dispose of 5,473,145 shares, with no shared voting or dispositive power. The holdings are attributed to certain BlackRock business units, and various underlying clients have the right to receive dividends or sale proceeds, but no individual client holds more than five percent of ORIC’s total common shares. BlackRock states the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of ORIC.
Oric Pharmaceuticals director Richard A. Heyman reported planned stock sales under a Rule 10b5-1 trading plan shared with RAHD Capital, LLC. On January 16, 2026, he sold 3,500 shares of common stock directly at a weighted average price of $12.0046, leaving 41,800 shares held directly. The same day, 3,200 additional shares were sold indirectly at the same weighted average price, with 213,072 shares then held of record by RAHD Capital, LLC, over which he has voting and investment power. In total, the filing notes a weighted average price for 6,700 shares sold in a price range of $12.00 to $12.03.
A holder of ORIC common stock has filed a notice to sell 6,400 shares under Rule 144. The planned sale is through J.P. Morgan Securities LLC on the Nasdaq, with an indicated aggregate market value of $76,800 and the class having 97,389,279 shares outstanding.
The shares to be sold were originally acquired on 07/31/2015 through a stock option exercise from the issuer, paid in cash on the same date. The filer represents that they do not know of any material adverse, nonpublic information about ORIC’s current or future operations.